These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23486415)

  • 1. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis.
    Orosa B; García S; Martínez P; González A; Gómez-Reino JJ; Conde C
    Ann Rheum Dis; 2014 Jan; 73(1):298-305. PubMed ID: 23486415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necessity of lysophosphatidic acid receptor 1 for development of arthritis.
    Miyabe Y; Miyabe C; Iwai Y; Takayasu A; Fukuda S; Yokoyama W; Nagai J; Jona M; Tokuhara Y; Ohkawa R; Albers HM; Ovaa H; Aoki J; Chun J; Yatomi Y; Ueda H; Miyasaka M; Miyasaka N; Nanki T
    Arthritis Rheum; 2013 Aug; 65(8):2037-47. PubMed ID: 23666827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
    Zhao J; Wei J; Weathington N; Jacko AM; Huang H; Tsung A; Zhao Y
    Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.
    David M; Machuca-Gayet I; Kikuta J; Ottewell P; Mima F; Leblanc R; Bonnelye E; Ribeiro J; Holen I; Vales RL; Jurdic P; Chun J; Clézardin P; Ishii M; Peyruchaud O
    J Biol Chem; 2014 Mar; 289(10):6551-6564. PubMed ID: 24429286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis.
    Jacobs JP; Pettit AR; Shinohara ML; Jansson M; Cantor H; Gravallese EM; Mathis D; Benoist C
    Arthritis Rheum; 2004 Aug; 50(8):2685-94. PubMed ID: 15334485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
    Miyabe Y; Miyabe C; Iwai Y; Yokoyama W; Sekine C; Sugimoto K; Harigai M; Miyasaka M; Miyasaka N; Nanki T
    Arthritis Res Ther; 2014 Oct; 16(5):461. PubMed ID: 25273676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice.
    Orosa B; Martínez P; González A; Guede D; Caeiro JR; Gómez-Reino JJ; Conde C
    J Bone Miner Metab; 2015 Jul; 33(4):383-91. PubMed ID: 24994065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
    Konda VR; Desai A; Darland G; Bland JS; Tripp ML
    Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis.
    Ruiz-Heiland G; Zhao Y; Derer A; Braun T; Engelke K; Neumann E; Mueller-Ladner U; Liu Y; Zwerina J; Schett G
    Ann Rheum Dis; 2014 Apr; 73(4):771-9. PubMed ID: 23632195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.
    Park E; Kim D; Lee SM; Jun HS
    Oncotarget; 2017 Apr; 8(16):27240-27251. PubMed ID: 28460477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
    Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells.
    Grevers LC; de Vries TJ; Everts V; Verbeek JS; van den Berg WB; van Lent PL
    Ann Rheum Dis; 2013 Feb; 72(2):278-85. PubMed ID: 22918932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
    Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
    Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic blockade of LPA
    Sánchez-Marín L; Ladrón de Guevara-Miranda D; Mañas-Padilla MC; Alén F; Moreno-Fernández RD; Díaz-Navarro C; Pérez-Del Palacio J; García-Fernández M; Pedraza C; Pavón FJ; Rodríguez de Fonseca F; Santín LJ; Serrano A; Castilla-Ortega E
    Neuropharmacology; 2018 May; 133():189-201. PubMed ID: 29378212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
    Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
    Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T; Yamamoto T
    Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice.
    Ishizuka Y; Moriwaki S; Kawahara-Hanaoka M; Uemura Y; Serizawa I; Miyauchi M; Shibata S; Kanaya T; Takata T; Taniguchi N; Niida S
    J Bone Miner Res; 2007 Dec; 22(12):1933-42. PubMed ID: 17680722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells.
    Nochi H; Tomura H; Tobo M; Tanaka N; Sato K; Shinozaki T; Kobayashi T; Takagishi K; Ohta H; Okajima F; Tamoto K
    J Immunol; 2008 Oct; 181(7):5111-9. PubMed ID: 18802115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.